Tag: VERVE – 101
The trial of base editing lowers cholesterol, but it raises safety concerns
A mid-stage trial of base editing drug VERVE-101 was reported at a meeting of the American Heart Association. Results showed that after 28 days, participants who received a high or low dose of VERVE-101 had their PCSK9 levels reduced by up to 84%. They also saw their cholesterol levels drop by over 50%. The trial will continue next year.
Read More